Varenicline gets safety nod
November 19, 2012
THERE is no increased risk of
cardiovascular events associated
with use of varenicline compared
with bupropion for smoking
cessation, according to a new
study.
Published in the British Medical
Journal, the Danish research looked
data from 35,852 patients (17,926
users of varenicline matched to
17,926 users of bupropion).
Researchers found 57 major
cardiovascular events among
varenicline users (6.9 cases per
1000 person years) compared with
60 events among bupropion users
(7.1 cases per 1000 person years).
In addition, Varenicline use was
not associated with an increased
risk of acute coronary syndrome
(1.20, 0.75 to 1.91), ischaemic
stroke (0.77, 0.40 to 1.48), and
cardiovascular death (0.51, 0.13 to
2.02).
The above article was sent to subscribers in Pharmacy Daily's issue from 19 Nov 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 Nov 12